Certara (NASDAQ:CERT) Posts Earnings Results, Misses Estimates By $0.03 EPS

Certara (NASDAQ:CERT) announced its earnings results on Tuesday. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03), Briefing.com reports. The firm had revenue of $93.31 million for the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. Certara’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter last year, the business posted $0.10 EPS. Certara updated its FY24 guidance to $0.41 to $0.46 EPS.

Certara Price Performance

Shares of CERT stock traded down $0.56 during trading hours on Friday, reaching $12.51. The company’s stock had a trading volume of 1,546,078 shares, compared to its average volume of 582,396. The firm’s 50 day simple moving average is $14.93 and its 200-day simple moving average is $16.47. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -32.08, a PEG ratio of 5.39 and a beta of 1.52. Certara has a fifty-two week low of $11.81 and a fifty-two week high of $19.87. The company has a quick ratio of 3.26, a current ratio of 3.26 and a debt-to-equity ratio of 0.27.

Analyst Upgrades and Downgrades

CERT has been the topic of a number of recent research reports. KeyCorp lowered their target price on Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. UBS Group reduced their price target on Certara from $20.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday. Robert W. Baird reduced their price target on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday. Barclays reduced their price target on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Finally, JMP Securities reissued a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $18.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.